Su Chinyu, Lichtenstein Gary R
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.
Gastroenterol Clin North Am. 2004 Jun;33(2):209-34, viii. doi: 10.1016/j.gtc.2004.02.004.
6-Mercaptopurine and azathioprine have become important therapeutic options for patients with inflammatory bowel disease (IBD). Although accumulating data in the literature have supported the use of these immunomodulators in the management of IBD, marked variation exists in the pattern of clinical practice regarding azathioprine or 6-mercaptopurine therapy in patients with IBD. This article provides a critical review of the data on the clinical efficacy and toxicities of 6-mercaptopurine and azathioprine in the management of IBD. Emerging literature on the potential application of pharmacogenetic testing and metabolite monitoring are also discussed.
6-巯基嘌呤和硫唑嘌呤已成为炎症性肠病（IBD）患者重要的治疗选择。尽管文献中积累的数据支持使用这些免疫调节剂来管理IBD，但在IBD患者中，关于硫唑嘌呤或6-巯基嘌呤治疗的临床实践模式存在显著差异。本文对6-巯基嘌呤和硫唑嘌呤在IBD管理中的临床疗效和毒性数据进行了批判性综述。还讨论了关于药物遗传学检测和代谢物监测潜在应用的新文献。
Zotero 插件